Clinical Trial Update: Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC [Phase 2]

View source ↗

Summary

An ongoing Phase 2 clinical trial evaluating Y-90 radioembolization with capecitabine and atezolizumab for oligometastatic colorectal cancer with liver metastas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Tecentriq (atezolizumab)
• Xeloda (capecitabine)
• Y-90

Snippet

Sponsor: Brown University | Conditions: Colorectal Carcinoma Metastatic in the Liver | Phase 2 | Status: RECRUITING